Corvus Nicks up on Releasing Preclinical Trial Data
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares just cleared breakeven Wednesday. The South San Francisco-based company, a clinical-stage biopharmaceutical concern, today announced preclinical data highlighting the potential of soquelitinib to treat systemic sclerosis will be presented today in a poster session at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is taking place June 11-14 in Barcelona.
The poster will be presented by Gonçalo Boleto, M.D., MSc, a rheumatologist at Centro Académico de Medicina de Lisboa, Portugal. It was selected as a top 10 abstract by the Emerging EULAR Network, a network of young rheumatologists and researchers in the field of rheumatology in Europe and beyond.
“There continues to be strong interest in the potential of ITK inhibition to provide a new approach to treating a broad range of diseases, including immune mediated fibrotic diseases such as systemic sclerosis,” said CEO Richard A. Miller.
“We look forward to presenting preclinical data to the audience at EULAR demonstrating that soquelitinib, our lead ITK inhibitor, may prevent lung damage, inflammation and pulmonary hypertension caused by systemic sclerosis. While our main focus is developing soquelitinib via our registration Phase 3 trial in peripheral T cell lymphoma and Phase 1 trial in atopic dermatitis, we may explore the potential of ITK in systemic sclerosis in future clinical trials or via partnerships.”
CRVS shares forged ahead 9.5 cents, or 2.2%, to $4.34.
